4.5 Article

Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line

期刊

PLOS NEGLECTED TROPICAL DISEASES
卷 9, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pntd.0003493

关键词

-

资金

  1. Tres Cantos Open Lab Foundation

向作者/读者索取更多资源

Background Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, represents a very important public health problem in Latin America where it is endemic. Although mostly asymptomatic at its initial stage, after the disease becomes chronic, about a third of the infected patients progress to a potentially fatal outcome due to severe damage of heart and gut tissues. There is an urgent need for new drugs against Chagas disease since there are only two drugs available, benznidazole and nifurtimox, and both show toxic side effects and variable efficacy against the chronic stage of the disease. Methodology/Principal Findings Genetically engineered parasitic strains are used for high throughput screening (HTS) of large chemical collections in the search for new anti-parasitic compounds. These assays, although successful, are limited to reporter transgenic parasites and do not cover the wide T. cruzi genetic background. With the aim to contribute to the early drug discovery process against Chagas disease we have developed an automated image-based 384-well plate HTS assay for T. cruzi amastigote replication in a rat myoblast host cell line. An image analysis script was designed to inform on three outputs: total number of host cells, ratio of T. cruzi amastigotes per cell and percentage of infected cells, which respectively provides one host cell toxicity and two T. cruzi toxicity readouts. The assay was statistically robust (Z values >0.6) and was validated against a series of known anti-trypanosomatid drugs. Conclusions/Significance We have established a highly reproducible, high content HTS assay for screening of chemical compounds against T. cruzi infection of myoblasts that is amenable for use with any T. cruzi strain capable of in vitro infection. Our visual assay informs on both anti-parasitic and host cell toxicity readouts in a single experiment, allowing the direct identification of compounds selectively targeted to the parasite.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Benznidazole for the treatment of Chagas disease

Irene Losada Galvan, Julio Alonso-Padilla, Nuria Cortes-Serra, Cristina Alonso-Vega, Joaquim Gascon, Maria Jesus Pinazo

Summary: The text emphasizes the importance of benznidazole as a treatment for Chagas disease and its potential future use with different treatment schemes. Chemical, pharmacokinetic, and pharmacodynamic structures are discussed, along with data from previous studies and ongoing research. Other topics covered include indications for treatment, challenges such as adverse effects and access barriers, and alternative strategies to improve treatment access and safety.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Article Chemistry, Medicinal

Design, synthesis, and evaluation of substrate - analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B

Soledad Natalia Gonzalez, Jonathan J. Mills, Dante Maugeri, Christopher Olaya, Breana L. Laguera, Jeffrey R. Enders, Julian Sherman, Ana Rodriguez, Joshua G. Pierce, Juan Jose Cazzulo, Edward L. D'Antonio

Summary: The study discovered a competitive inhibitor Compound B targeting ribose 5-phosphate isomerase type B (RPI-B), which exhibited significant trypanocidal activity against T. cruzi infective life-stages. By targeting the active site residue Cys-69, this inhibitor provided a proof-of-concept for the development of next generation inhibitors with potential prodrug groups to treat Chagas' disease in the future.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Article Biochemistry & Molecular Biology

Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds

Nieves Martinez-Peinado, Clara Martori, Nuria Cortes-Serra, Julian Sherman, Ana Rodriguez, Joaquim Gascon, Jordi Alberola, Maria-Jesus Pinazo, Alheli Rodriguez-Cortes, Julio Alonso-Padilla

Summary: The study found that 17-DMAG has a strong inhibitory effect on T. cruzi, particularly during the intracellular replicative stage of the parasite. Molecular docking results suggest that 17-DMAG may bind T. cruzi Hsp90 homologue Hsp83 with good affinity. However, evaluation in a mouse model of chronic T. cruzi infection did not show parasite growth inhibition, highlighting challenges in transitioning from in vitro assays to preclinical drug development stages.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Pathology

Development and Evaluation of a Three-Dimensional Printere-Based DNA Extraction Method Coupled to Loop Mediated Isothermal Amplification for Point-of-Care Diagnosis of Congenital Chagas Disease in Endemic Regions

Diana P. Wehrendt, Julio Alonso-Padilla, Bo Liu, Lizeth Rojas Panozo, Silvia Rivera Nina, Lilian Pinto, Daniel Lozano, Albert Picado, Marcelo Abril, Maria J. Pinazo, Joaquim Gascon, Faustino Torrico, Season Wong, Alejandro G. Schijman

Summary: Vertical transmission of Trypanosoma cruzi causes congenital Chagas disease, which requires early diagnosis and treatment. A LAMP technology coupled with automated DNA extraction device showed promise for point-of-care early diagnosis, with high sensitivity and specificity compared to traditional microscopy-based methods.

JOURNAL OF MOLECULAR DIAGNOSTICS (2021)

Article Microbiology

Identification of Trypanosoma cruzi Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs

Nieves Martinez-Peinado, Nuria Cortes-Serra, Julian Sherman, Ana Rodriguez, Juan M. Bustamante, Joaquim Gascon, Maria-Jesus Pinazo, Julio Alonso-Padilla

Summary: Chagas disease, caused by the parasite Trypanosoma cruzi, has its greatest burden in Latin America. Existing treatments present toxicity and variable efficacy, highlighting the urgent need for new therapeutic strategies. Drug repositioning offers a fast and low-cost approach to identify safer and more effective chemotherapies for Chagas disease.

MICROORGANISMS (2021)

Article Chemistry, Medicinal

Synthesis, biochemical, and biological evaluation of C2 linkage derivatives of amino sugars, inhibitors of glucokinase from Trypanosoma cruzi

Scott B. Green, Robert J. Lanier Jr, Shane M. Carey, David R. Morgan, Hanna Gracz, Julian Sherman, Ana Rodriguez, Edward L. D'Antonio

Summary: The screening of eighteen amino sugar analogues against Trypanosoma cruzi glucokinase revealed five on-target confirmed inhibitors, all from the D-GlcN series. Four of these compounds were identified as strong TcGlcK inhibitors, while three showed significant in vitro anti-T. cruzi activity. Compounds 5 and 6 were further evaluated biochemically, with formal Ki values determined and exhibiting competitive inhibition mode for TcGlcK.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Letter Respiratory System

Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients

Marisol Zuniga, Claudia Gomes, Steven E. Carsons, Michael T. Bender, Paolo Cotzia, Qing Robert Miao, David C. Lee, Ana Rodriguez

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Infectious Diseases

Autoimmunity to phosphatidylserine and anemia in African Trypanosome infections

Juan Rivera-Correa, Joseph Verdi, Julian Sherman, Jeremy M. Sternberg, Jayne Raper, Ana Rodriguez

Summary: The study found evidence of autoimmunity against phosphatidylserine in Trypanosoma brucei infected mice and Human African Trypanosomiasis patients, suggesting a potential link between autoimmunity and anemia.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Article Plant Sciences

Anti-Trypanosoma cruzi activity of alkaloids isolated from Habranthus brachyandrus (Amaryllidaceae) from Argentina

Nieves Martinez-Peinado, Javier E. Ortiz, Maria Jesus Pinazo, Joaquim Gascon, Alejandro Tapia, German Roitman, Jaume Bastida, Gabriela E. Feresin, Julio Alonso-Padilla

Summary: This study identified alkaloids with anti-T. cruzi activity from Habranthus brachyandrus collected in Argentina. The alkaloid ismine showed specific activity against the parasite and low toxicity against liver cells. These findings provide a new direction for the development of drugs for Chagas disease.

PHYTOMEDICINE (2022)

Article Food Science & Technology

Computer-Aided Analysis of West Sub-Saharan Africa Snakes Venom towards the Design of Epitope-Based Poly-Specific Antivenoms

Albert Ros-Lucas, Pascal Bigey, Jean-Philippe Chippaux, Joaquim Gascon, Julio Alonso-Padilla

Summary: Snakebite envenomation causes a significant number of deaths each year, and the production of antivenoms is often limited by their variable potency and accessibility. This study presents a method based on sequence conservation and protein structural features to prioritize therapeutic epitopes from snake venom. The selected epitopes are applicable to the most medically important snake species in West Sub-Saharan Africa and can be customized for venom sequence analysis in other regions.

TOXINS (2022)

Article Biochemistry & Molecular Biology

A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease

Alba L. Montoya, Elisa G. Carvajal, Uriel Ortega-Rodriguez, Igor L. Estevao, Roger A. Ashmus, Sohan R. Jankuru, Susana Portillo, Cameron C. Ellis, Colin D. Knight, Julio Alonso-Padilla, Luis Izquierdo, Maria-Jesus Pinazo, Joaquim Gascon, Veronica Suarez, Douglas M. Watts, Iliana R. Malo, Janine M. Ramsey, Belkisyole Alarcon De Noya, Oscar Noya, Igor C. Almeida, Katja Michael

Summary: Chagas disease, caused by the parasite Trypanosoma cruzi, affects millions of people worldwide. The diagnosis and treatment assessment of Chagas disease is challenging due to parasite diversity and the lack of biomarkers. This study explores the potential of glycosylphosphatidylinositol-anchored mucins as biomarkers for diagnosis and treatment assessment in Chagas disease patients.

MOLECULES (2022)

Article Microbiology

Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses against Trypanosoma cruzi

Nieves Martinez-Peinado, Juan Carlos Gabaldon-Figueira, Ignacio Martinez-Anon, Cristian Rodriguez-Gordo, Raquel Robleda-Castillo, Maria-Jesus Pinazo, Pascal Bigey, Joaquim Gascon, Julio Alonso-Padilla

Summary: The serum parasite inhibition assay is a valuable tool for evaluating changes in Trypanosoma cruzi infection by exposing infective trypomastigotes to serum samples from infected patients. There is a clear correlation between the reactivity of the samples to the whole-parasite lysates by ELISA and the inhibitory effect. This study confirms the importance of the assay for measuring antibody efficacy.

MICROORGANISMS (2023)

Article Plant Sciences

Candimine from Hippeastrum escoipense (Amaryllidaceae): Anti-Trypanosoma cruzi activity and synergistic effect with benznidazole

Javier E. Ortiz, Mauricio Pineiro, Nieves Martinez-Peinado, Patricia Barrera, Miguel Sosa, Jaume Bastida, Julio Alonso-Padilla, Gabriela E. Feresin

Summary: This study evaluated the anti-T. cruzi activity of the alkaloid candimine isolated from a plant, and assessed its combination effect with benznidazole, an existing drug. The results showed that candimine exhibited high anti-parasitic activity, and its combination with benznidazole enhanced its efficacy against T. cruzi, suggesting its potential as a new therapy for Chagas disease.

PHYTOMEDICINE (2023)

Article Medicine, Research & Experimental

Endothelial transcriptomic analysis identifies biomarkers of severe and cerebral malaria

Claudia Gomes, Rosauro Varo, Miquel Duran-Frigola, Antonio Sitoe, Rubio Bila, Sonia Machevo, Alfredo Mayor, Quique Bassat, Ana Rodriguez

Summary: Malaria can progress from an uncomplicated infection to a life-threatening severe disease. Early symptoms are often nonspecific, making it difficult to identify patients at high risk. By analyzing the transcriptomic response of human brain microvascular endothelial cells to Plasmodium falciparum-infected erythrocytes, several biomarkers have been identified to distinguish uncomplicated from severe malaria, as well as to differentiate children with cerebral malaria within the severe malaria group.

JCI INSIGHT (2023)

暂无数据